Cardiovascular Diseases Clinical Trial
Official title:
Women's Health Study of Low-dose Aspirin and Vitamin E in Apparently Healthy Women
The purpose of this study is to evaluate the effects of low-dose aspirin and vitamin E in primary prevention of cardiovascular disease and cancer in apparently healthy women.
BACKGROUND:
Various doses of aspirin have been shown to be effective in preventing thrombosis or
vascular occlusion in several clinical conditions. Short-term studies have documented the
efficacy of aspirin in preventing occlusion of saphenous vein bypass grants, preventing
myocardial infarction in patients with unstable angina, preventing transient ischemic
attacks and stroke in men with cerebral vascular disease, preventing occlusion of injured
coronary arteries following transluminal angioplasty and aiding in reducing myocardial
infarction and total mortality in patients receiving fibrinolytic therapy. Additionally,
aspirin has been effective in the secondary prevention of myocardial infarction in subjects
with known coronary artery disease. The results of the Physicians' Health Study, a
large-scale primary prevention trial of aspirin in male physicians, have shown a decrease in
myocardial infarction, a non-significant increase in cerebral vascular events, and no
difference in overall mortality. However, few studies have addressed the efficacy of aspirin
in vascular diseases in women, and it is possible that the risk to benefit ratio may be
different in women. Specifically, there have been no large primary prevention trials in
women, who are at risk of coronary heart disease, especially after menopause.
DESIGN NARRATIVE:
The Women's Health Study (WHS) is a randomized, double-blind, placebo-controlled trial using
a 2x2 factorial design. The WHS is sponsored by both NHBLI (HL080467) and NCI (CA047988).
Approximately 1.75 million female health professionals were contacted by mail to determine
if they were suitable for inclusion in the study. A three-month run-in phase was performed
to screen out those with poor compliance. Randomization, which began in February 1993 and
ended in January 1996, was stratified on five-year age groups. A total of 39,876
participants were randomly assigned to either Vitamin E (600 IU every other day) or placebo;
and to aspirin (100 mg every other day) or placebo. IN the 2x2 factorial design, women were
randomly assigned to active aspirin and placebo vitamin E (n=9,968), placebo aspirin and
active vitamin E (n=9,971), active aspirin and active vitamin E (n=9,966), or placebo
aspirin and placebo vitamin E (n=9,971). A description of the characteristics of women in
these 4 groups is provided in J Women's Health Gend Based Med 2000;9:19-27. In the main
analyses, all women on active aspirin (n=19,934) were compared to women on placebo aspirin
(n=19,942); and all women on active vitamin E (n=19,937) were compared to women on placebo
aspirin (n=19,939).
As part of the initial trial, pre-randomization blood samples from 28,345 participants were
frozen and stored for genetic analysis which has been supported by non-federal sources.
The primary endpoint is the reduction of the risk of all important vascular events (a
combined endpoint of nonfatal myocardial infarction, nonfatal stroke, and total
cardiovascular death) and a decrease in the incidence of total malignant neoplasms of
epithelial cell origin. Secondary endpoints are the individual components of the combined
endpoints. Compliance is measured by replies to a questionnaire sent out every year. The
trial was completed in 2004 and results were published in 2005 (N Engl J Med
2005;352:1293-304; JAMA 2005;294:47-55; JAMA 2005;294:56-65).
Currently, women are being followed on an observational basis.
;
Allocation: Randomized, Intervention Model: Factorial Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05654272 -
Development of CIRC Technologies
|
||
Recruiting |
NCT05650307 -
CV Imaging of Metabolic Interventions
|
||
Recruiting |
NCT04515303 -
Digital Intervention Participation in DASH
|
||
Completed |
NCT04056208 -
Pistachios Blood Sugar Control, Heart and Gut Health
|
Phase 2 | |
Recruiting |
NCT04417387 -
The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
|
||
Not yet recruiting |
NCT06211361 -
Cardiac Rehabilitation Program in Patients With Cardiovascular Disease
|
N/A | |
Not yet recruiting |
NCT06032572 -
Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE)
|
N/A | |
Recruiting |
NCT04514445 -
The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
|
||
Enrolling by invitation |
NCT04253054 -
Chinese Multi-provincial Cohort Study-Beijing Project
|
||
Completed |
NCT03273972 -
INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers
|
N/A | |
Completed |
NCT03680638 -
The Effect of Antioxidants on Skin Blood Flow During Local Heating
|
Phase 1 | |
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Completed |
NCT04083846 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed)
|
Phase 1 | |
Completed |
NCT04083872 -
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting)
|
Phase 1 | |
Completed |
NCT03693365 -
Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
|
||
Completed |
NCT03466333 -
Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia
|
Phase 2 | |
Completed |
NCT03619148 -
The Incidence of Respiratory Symptoms Associated With the Use of HFNO
|
N/A | |
Completed |
NCT04082585 -
Total Health Improvement Program Research Project
|
||
Completed |
NCT05132998 -
Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors
|
N/A | |
Completed |
NCT05067114 -
Solutions for Atrial Fibrillation Edvocacy (SAFE)
|